KR20230093499A - 인간 대상체에서 타우를 감소시키는 방법 - Google Patents

인간 대상체에서 타우를 감소시키는 방법 Download PDF

Info

Publication number
KR20230093499A
KR20230093499A KR1020237017869A KR20237017869A KR20230093499A KR 20230093499 A KR20230093499 A KR 20230093499A KR 1020237017869 A KR1020237017869 A KR 1020237017869A KR 20237017869 A KR20237017869 A KR 20237017869A KR 20230093499 A KR20230093499 A KR 20230093499A
Authority
KR
South Korea
Prior art keywords
amino acid
seq
acid sequence
chain variable
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237017869A
Other languages
English (en)
Korean (ko)
Inventor
웬디 알. 갤펀
마르텐 티머스
톰 리븐 케이. 제이콥스
파르타 낸디
링쥬 리
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20230093499A publication Critical patent/KR20230093499A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237017869A 2020-10-26 2021-10-25 인간 대상체에서 타우를 감소시키는 방법 Pending KR20230093499A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105,804 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (1)

Publication Number Publication Date
KR20230093499A true KR20230093499A (ko) 2023-06-27

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237017869A Pending KR20230093499A (ko) 2020-10-26 2021-10-25 인간 대상체에서 타우를 감소시키는 방법

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Also Published As

Publication number Publication date
MX2023004831A (es) 2023-07-12
TW202233666A (zh) 2022-09-01
US20220127345A1 (en) 2022-04-28
IL302386A (en) 2023-06-01
CA3199806A1 (en) 2022-05-05
AU2021367878A1 (en) 2023-06-22
JP2023546504A (ja) 2023-11-02
EP4232155A1 (en) 2023-08-30
WO2022090158A1 (en) 2022-05-05
CN116916955A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
KR100767146B1 (ko) Ａβ 펩티드를 격리시키는 인간화 항체
TWI634126B (zh) 抗－N3pGlu 類澱粉β肽抗體及其用途
TWI595007B (zh) 抗ｍｃａｍ抗體及相關使用方法
TW201900682A (zh) 抗ｐｈｆ－ｔａｕ抗體及其用途
JP2020512368A (ja) シヌクレイノパチーを治療するための組成物及び方法
US20240025978A1 (en) Methods for treating complement-mediated diseases
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
KR20250107906A (ko) 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
JP2023548005A (ja) 抗トランスサイレチン抗体およびその使用方法
JP2024547001A (ja) 抗アミロイドβプロトフィブリル抗体及び抗タウ抗体を使用する方法
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
HK40100364A (zh) 减少人类受试者中的tau的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN116829582A (zh) 安全施用抗Tau抗体的方法
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
HK40100358A (zh) 安全施用抗tau抗体的方法
EA047298B1 (ru) Антитела к phf-тау и их применение
WO2026035942A1 (en) Combinatorial therapy for alzheimer's disease
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D16-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D17-EXM-PA0302 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902